Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript
MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study
Mirum enrolls the first participant in its phase II BLOOM study investigating MRM-3379 for treating Fragile X syndrome.
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2025 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. ( MIRM ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Peter Radovich - COO & President Joanne M. Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Abdulqudus Tahlil - JPMorgan Chase & Co, Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Mark Hitrik - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Thome - TD Cowen, Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Ryan Mcelroy - Leerink Partners LLC, Research Division Rohit Bhasin - Morgan Stanley, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Presentation Operator Hello, and welcome to the Mirum Pharmaceuticals Third Quarter 2025 Financial Results and Business Update.
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.3 per share a year ago.
Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?
MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
Mirum Pharmaceuticals, Inc. (MIRM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Christopher Peetz - CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.
Mirum Pharmaceuticals: Q2 Results Continue To Show Positive Momentum
Mirum Pharmaceuticals continues to outperform, beating revenue and earnings expectations for two consecutive quarters and raising guidance. Livmarli, Mirum's flagship drug, is driving strong revenue growth, with approvals in both the U.S. and Europe to treat symptoms of rare liver diseases. The analyst community remains unanimously bullish on the stock, and more than a half dozen analyst firms raised their price targets following Q2 results.
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Eric H. Bjerkholt - Chief Financial Officer Joanne M.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.52 per share a year ago.
